Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9304524 | 0.93 | SIGMAR1 (0.55) | CNR1POLBSIGMAR1CHRM2CHRM4 | |
| SCHEMBL13297902 | 0.85 | SLC6A3 (0.50) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11542316 | 0.84 | SIGMAR1 (0.51) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6212322 | 0.79 | HTR6 (0.43) | SIGMAR1 | |
| SCHEMBL15591791 | 0.79 | CNR1 (0.53) | CNR1POLBSIGMAR1CNR2 | |
| SCHEMBL11620971 | 0.78 | SIGMAR1 (0.54) | SIGMAR1 | |
| SCHEMBL31121639 | 0.77 | HTR6 (0.56) | SIGMAR1 | |
| SCHEMBL2338975 | 0.77 | HTR6 (0.56) | SIGMAR1 | |
| SCHEMBL11542289 | 0.77 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL20768130 | 0.75 | CNR1 (0.48) | CNR1POLBSIGMAR1CNR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258822-A1 | PRECURSORS OF PERIPHERALLY RESTRICTED CANNABINOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9656981-B2 | Peripherally-acting cannabinoid receptor agonists for chronic pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656981-B2 | Peripherally-acting cannabinoid receptor agonists for chronic pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656981-B2 | Peripherally-acting cannabinoid receptor agonists for chronic pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| WO-2014015298-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-01-23 | — | — | WO | disclosed |
| US-5292736-A | Morpholinoalkylindenes as antiglaucoma agents | STERLING WINTHROP INC. (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | CNR2, CNR1, OPRL1 | CNR1 2/4885POLB 2262/4885SIGMAR1 118/4885 |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | CNR2, CNR1, OPRL1 | CNR1 2/4885POLB 2262/4885SIGMAR1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.